A growing body of evidence has indicated that long non-coding RNAs (lncRNAs) serve as competing endogenous RNAs (ceRNAs) during
oncogenesis. In this study, the qRT-PCR results indicated that the
lncRNA PVT1 is overexpressed in
osteosarcoma and decreased the survival rate of
osteosarcoma patients. MTT and clonal colony formation assays were used to detect the effect of PVT1 on proliferation, and flow cytometry was performed to assess apoptosis and the cell cycle. A Transwell assay was used to analyze migration and invasion. The results revealed that silencing PVT1 by
siRNA inhibited proliferation, migration and invasion and promoted apoptosis and cell cycle arrest in
osteosarcoma cells. Furthermore, a gene microarray was used to screen differentially expressed
miRNAs associated with PVT1. The interaction between PVT1 and
miRNAs was then analyzed by qRT-PCR and
luciferase reporter gene assay. We found that PVT1 negatively regulated miR-195 in
osteosarcoma cells. Simultaneously, we found that silencing PVT1 by
siRNA suppressed proliferation, migration and invasion and promoted cell cycle arrest and apoptosis via miR-195 in
osteosarcoma cells. Moreover, silencing PVT1 by
siRNA inhibited BCL2, CCND1, and FASN
protein expression via miR-195 in
osteosarcoma cells, and BCL2 inhibited the si-PVT1#1-induced apoptosis of U2OS cells. CCND1 inhibited the cell cycle arrest of U2OS cells induced by si-PVT1#1. FASN promoted the invasiveness U2OS cells, which was inhibited by si-PVT1#1. Therefore, our study demonstrated that PVT1 may be a therapeutic target for treatment of
osteosarcoma.